---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-168479"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2024-06-26T23:59:59+00:00"
generated_at: "2026-06-01T01:48:38.738597+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Taysha launches $75M public offering; reports positive clinical data in Rett syndrome

## Summary
- Commenced underwritten public offering of up to $75M in common stock and pre-funded warrants; underwriters have 30-day option for additional 15%.
- TSHA-102 in Rett syndrome shows sustained improvements in motor, hand function, and seizure reduction in two adult patients at 52 and 36 weeks.
- IDMC approved dose escalation to cohort 2; first high-dose patient dosed in Q2 2024; initial data from cohort 2 expected H2 2024.
- Received RMAT designation from FDA for TSHA-102 in April 2024, providing expedited development pathway.

## SEC filing metadata
- accession: 0001193125-24-168479
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2024-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312524168479/0001193125-24-168479-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312524168479/d834815d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-168479
- JSON: https://secwatch.observer/filing/0001193125-24-168479.json
- Plain text: https://secwatch.observer/filing/0001193125-24-168479.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.